Sign In
Buy CLDX
$33.41
+0.98 (+3.02%)
At Close: Jun 22, 2026
Celldex Presents Preliminary Data from Ongoing CDX-527 Phase 1 Dose Escalation Trial at the 2021 ASCO Annual Meeting
09:01am, Friday, 04'th Jun 2021
HAMPTON, N.J., June 04, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced preliminary data from the Company's Phase 1 dose escalation study of PD-L1xCD27 bispecific ant
HAMPTON, N.J., June 01, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing results from the Phase 1b study of CDX-0159 in patients with antih
Celldex to Present at the Jefferies 2021 Virtual Healthcare Conference
04:01pm, Wednesday, 26'th May 2021
HAMPTON, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a fireside chat at the Jefferies 2021 Virtual Health
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
07:32pm, Thursday, 06'th May 2021
Celldex (CLDX) delivered earnings and revenue surprises of -31.25% and -39.38%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Celldex Presents Promising Data from ILT4/PD-(L)1 Bispecific Antibody Program at AACR 2021
04:01pm, Monday, 12'th Apr 2021
HAMPTON, N.J., April 12, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the presentation of promising data from the Company's growing bispecific platform at the Amer
Could Celldex Be a Millionaire-Maker Stock?
06:13am, Saturday, 10'th Apr 2021
Not at its present valuation, it's not.
Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2020 Results
04:01pm, Monday, 29'th Mar 2021
HAMPTON, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31, 2020.
Why Celldex Therapeutics Stock Is Tanking Today
12:06pm, Monday, 29'th Mar 2021
The biotech reported interim results from a phase 1b study.
Celldex Reports 80% Complete Response Rate in Interim Data Update from Phase 1b study of CDX-0159 in Chronic Inducible Urticaria
06:30am, Monday, 29'th Mar 2021
--CDX-0159 generally well tolerated to date-- --Conference call to be held at 7:45 a.m. ET today-- HAMPTON, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today re
Celldex Therapeutics Announces Fireside Chat Presentation at the H.C. Wainwright Global Life Sciences Conference
01:00pm, Friday, 05'th Mar 2021
HAMPTON, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the Company's participation in a fireside chat at the H.C. Wainwright Global Life Sciences Co
Celldex Therapeutics To Test CDX-0159 In Chronic Itchy Skin Disorder
06:01am, Tuesday, 23'rd Feb 2021
Celldex Therapeutics Inc (NASDAQ: CLDX) will expand the clinical development of CDX-0159 into prurigo nodularis (PN), a chronic skin disease characterized by the development of hard, intensely itc
Celldex Therapeutics to Expand Development of CDX-0159 into Prurigo Nodularis (PN)
04:01pm, Monday, 22'nd Feb 2021
--Dermatological indication characterized by chronic, intensely itchy nodules; mast cell activation believed to play an important role in amplifying chronic itch and neuroinflammation-- --Potential to
Celldex Therapeutics to Present at 10th Annual SVB Leerink Global Healthcare Conference
08:01am, Monday, 22'nd Feb 2021
HAMPTON, N.J., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that the Company will participate in a fireside chat at the 10th Annual SVB Leerink Global Hea
Celldex: New Monoclonal Therapeutic Line, 1Q21's CDX-0159's Initial Trial Data, And More
02:28pm, Sunday, 17'th Jan 2021
Celldex Therapeutics is a biopharmaceutical company focused on developing monoclonal and bispecific antibody-based therapeutics. Celldex's new pipeline is now made up of 3 Phase 1 immunotherapies/targ
Do Options Traders Know Something About Celldex (CLDX) Stock We Don't?
09:47am, Friday, 08'th Jan 2021
Investors need to pay close attention to Celldex (CLDX) stock based on the movements in the options market lately.
